GlassScriptPhysician profile
Leigh Luna
NPI 1144677824
$68,690.03
in general payments reported to CMS, 2019-2025
34 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $738 · 2023: $1,287 · 2024: $2,336 · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Consulting Fee: $6,750 · Food and Beverage: $6,498 · Travel and Lodging: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,877.00 |
| Consulting Fee | $6,750.00 |
| Food and Beverage | $6,498.49 |
| Travel and Lodging | $1,409.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $62,545.59 | 2022-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $699.55 | 2021-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $549.94 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $469.74 | 2021-2025 | Lokelma, Breztri, Tezspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.05 | 2022-2025 | Xifaxan |
| Abbvie INC. | $395.95 | 2023-2025 | |
| Novo Nordisk INC | $383.05 | 2022-2025 | Wegovy, Ozempic |
| Amgen INC. | $308.16 | 2023-2025 | Repatha, Evenity |
| Ucb, INC. | $272.50 | 2024-2025 | Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $243.65 | 2024-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Gilead Sciences, INC. | $232.64 | 2025 | Yeztugo |
| Alnylam Pharmaceuticals INC. | $175.55 | 2024 | Amvuttra |
| Pfizer INC. | $160.54 | 2024-2025 | |
| Lilly USA, LLC | $158.62 | 2021-2024 | Trulicity, Jardiance |
| Sumitomo Pharma America, INC. | $152.73 | 2023 | Gemtesa, Aptiom |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $138.03 | 2023-2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $123.91 | 2024 | Xarelto |
| Ani Pharmaceuticals, INC. | $112.58 | 2025 | Purified Cortrophin Gel |
| Eisai INC. | $109.22 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $99.75 | 2025 | |
| Axonics, INC. | $94.57 | 2024 | Axonics |
| Glaxosmithkline, LLC. | $94.24 | 2022 | |
| Radius Health, INC. | $91.27 | 2025 | Tymlos |
| Alpha Cognition USA, INC. | $81.47 | 2025 | Zunveyl |
| Biohaven Pharmaceutical Holding Company LTD. | $77.55 | 2022 | |
| Cvrx, INC. | $73.34 | 2021 | |
| Sunovion Pharmaceuticals INC. | $72.41 | 2021 | |
| Alkermes, INC. | $68.01 | 2024 | Lybalvi |
| Axsome Therapeutics, INC. | $61.51 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $57.61 | 2023 | Krystexxa |
| Acorda Therapeutics, INC | $57.45 | 2023 | Inbrija |
| Phathom Pharmaceuticals, INC. | $55.99 | 2024 | Voquezna |
| Sk Life Science, INC. | $30.30 | 2025 | |
| Urovant Sciences INC | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Luna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.